After years and years of research and hopes for a cancer cure, a group of Israeli scientists has also come forward with another hope for cancer. The Israeli biotech company Accelerated Evolution Biotechnologies (AEBi) claimed that they will have the cure for cancer within a year. They added, "Our cancer cure will be effective from day one, will last a duration of a few weeks, and will have no or minimal side-effects at a much lower cost than most other treatments on the market," Aridor, board chairman of AEBi told The Jerusalem Post. "Our solution will be both generic and personal," he added.
According to The Jerusalem Post, AEBi's cancer cure is called MuTaTo, which stands for "multi-target toxin." It attacks cancer cells with several peptides — compounds comprising chains of amino acids — at once, and this multi-pronged attack is key to the treatment's efficacy, the company says.
"We made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer," AEBi CEO Ilan Morad told the Post. "The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used."
"Instead of attacking receptors one at a time, we attack receptors three at a time," he continued. "Not even cancer can mutate three receptors at the same time."
However, many researchers have dismissed this supposedly ground-breaking news as shaky stating that the claims are categorically untrue. They added that cancers can have anywhere from one to tens of thousands of DNA mutations in their genomes, many of these being the "receptors" Morad vaguely refers to, hence Morad's logic remains extremely shaky.